Laprem

Lapatinib, the active ingredient in Laprem, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It targets HER2‑positive metastatic breast cancer and HER2‑positive gastric cancer, providing a therapeutic option for patients whose tumors overexpress these receptors.

GNH USA supplies Laprem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Laprem (lapatinib) acts on the HER2/EGFR signaling pathway and is indicated for the following oncologic conditions: - HER2‑positive metastatic breast cancer: used to slow tumor growth and extend progression‑free survival. - HER2‑positive gastric cancer: used to inhibit tumor proliferation in advanced disease. - Combination therapy for HER2‑positive breast cancer: administered with capecitabine or trastuzumab to enhance anti‑tumor effect.

Common Side Effects: - Diarrhea: mild to moderate watery stools. - Rash: maculopapular skin eruption, often on the trunk. - Nausea: occasional feeling of queasiness. - Fatigue: generalized tiredness. - Stomatitis: inflammation of the mouth lining. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - Cardiac dysfunction: decreased left ventricular ejection fraction. - Interstitial lung disease: breathlessness and cough. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Pancreatitis: abdominal pain with elevated enzymes.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly. - Monitor liver function: obtain baseline and periodic LFTs during treatment. - Assess cardiac function: perform echocardiogram or MUGA scan before and during therapy. - Check for QT prolongation: obtain ECG if risk factors are present. - Avoid use in severe hepatic impairment: dose adjustment may be required. - Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Lapatinib may interact with several concomitant medicines, requiring dose adjustments or monitoring. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lapatinib exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering plasma levels. - Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously. Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of myopathy; consider dose reduction. - Digoxin: possible increase in serum concentration; monitor cardiac levels.